Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Hemostemix Inc V.HEM

Alternate Symbol(s):  HMTXF

Hemostemix Inc. is a Canada-based clinical-stage biotechnology company. The Company’s principal business is to develop, manufacture and commercialize blood-derived stem cell therapies to treat various diseases. It is an autologous stem cell therapeutics company that holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01 is a lead clinical-stage candidate, like NCP-01 and CCP-01, is generated from the patient’s blood. The Company is engaged in providing treatment for ischemia, such as ischemic cardiomyopathy, angina, peripheral arterial disease including critical limb ischemia. The Company’s proprietary technology is a personalized regenerative therapy that is administered to a patient within seven days of the initial blood draw. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd., and PreCerv Inc.


TSXV:HEM - Post by User

Comment by Walterthedogon Jun 01, 2021 4:07pm
298 Views
Post# 33304786

RE:RE:RE:Holding long

RE:RE:RE:Holding longThe questions and rumors that we still need data from Aspire have been circulating on CEO.ca and elsewhere for a while now and if we had what we needed he could have dispelled that bad info easily but has not. and even when i directly questioned him about it in the agm, i got an answer describing the source data verification procedure so I'm fully expecting in August to hear that we can not complete the trial analysis due to missing base info or something like that. It just sucks and I get that management is in a very tough spot and theyre doing what they can but they have completely lost investors faith and we need to know all the risks instead of the rosy outlook we've been getting. The way I see it is we will have to conclude the lawsuits in order to even see if ACP is effective and that there is no moving forward in any way until a judgement is made. It will become a battle of attrition between Aspire and Hemostemix and whoever can pay their lawyers more and for a longer period of time will win the rights to the data and the tech. The delaware case has Aspire on the defense but the Florida case docs show that Aspire may actually have sole ownership of the technology. It's complex and I'm not a lawyer but that case is not a done deal as Smeenk has been saying. I see a long dark road ahead for hemostemix and they probably won't be able to suck any more capital out of investors until they can shed some of the risk. Im already down 70% so I'm here until the bitter end. Good luck fellow idiots. Lol
<< Previous
Bullboard Posts
Next >>